Ignite Creation Date:
2024-05-06 @ 4:06 AM
Last Modification Date:
2024-10-26 @ 11:43 AM
Study NCT ID:
NCT02453282
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-18
First Post:
2015-05-20
Brief Title:
Phase III Open Label First Line Therapy Study of MEDI 4736 Durvalumab With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer NSCLC
Sponsor:
Organization:
AstraZeneca